ImmVirX Reports Encouraging Phase 1b Clinical Data for IVX037 and Highlights Broad Preclinical Activity of IVX055 at AACR 2026
IVX037 data demonstrate favourable safety profile, abscopal effects and enhanced activity in KRAS/BRAF-mutant tumours; IVX055 shows potent anti-tumour activity across multiple solid tumour types Melbourne, Australia 21 April 2026 – ImmVirX Pty Limited, a life sciences company developing next-generation, receptor-targeted oncolytic RNA immunotherapies, today announced the presentation of new clinical and translational data for its […]
